What is Crexont?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Crexont?

Crexont (IPX203) is a novel oral extended-release carbidopa-levodopa formulation approved for treating Parkinson's disease that provides longer-duration levodopa plasma concentrations than immediate-release formulations while requiring fewer daily doses. 1

Pharmacological Profile

Crexont is designed with a dual-action mechanism that rapidly achieves levodopa plasma concentrations similar to immediate-release (IR) carbidopa-levodopa while maintaining therapeutic levels for an extended duration compared to other oral carbidopa-levodopa products. 1 This extended-release formulation addresses the challenge of motor fluctuations in Parkinson's disease by providing more stable dopaminergic stimulation throughout the day.

Clinical Efficacy

In the pivotal phase 3 clinical trial, Crexont demonstrated superior clinical benefit with fewer daily doses compared to immediate-release carbidopa-levodopa. 1 The majority of patients (84%) achieved optimal symptom control with three-times-daily dosing, though the approved regimen allows for 2 to 4 times per day administration based on individual clinical response. 1

Conversion and Dosing Strategy

When converting patients from immediate-release carbidopa-levodopa to Crexont, the conversion ratio is approximately 2.8 to 2.9 mg of Crexont per mg of immediate-release levodopa. 1 The conversion process involves:

  • Initial dosing based on the patient's most frequent single dose of their stable immediate-release regimen 1
  • Starting with three-times-daily administration for most patients 1
  • Subsequent titration based on clinical response to achieve optimal motor control 1
  • Final dosing frequency ranging from 2 to 4 times daily depending on individual needs 1

Of 589 patients previously treated with immediate-release carbidopa-levodopa in the pivotal trial, 506 (86%) successfully completed conversion to Crexont, demonstrating the feasibility of this transition strategy. 1

Clinical Context

This medication represents an advancement in Parkinson's disease management by addressing the "wearing-off" phenomenon that commonly occurs with immediate-release formulations, potentially improving quality of life through more consistent motor control and reduced dosing frequency. 1

References

Related Questions

Can CREST (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) syndrome be diagnosed without calcinosis?
What is the CREST (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) variant on Antinuclear Antibody (ANA)?
Do patients with CREST syndrome need to follow up with their healthcare provider?
What labs and tests are recommended for a patient with a history of CREST (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) syndrome presenting with paresthesia (pin prick sensation) and testicular itching without a rash?
Can Crest syndrome (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) cause generalized pruritus?
What is the treatment for Staphylococcus (Staph) aureus in urine?
What is the recommended dosing for amisulpiride in the treatment of schizophrenia?
What is the treatment for a patient with a positive urine culture (urine cx) showing a bacterial infection?
How to manage a patient in the Intensive Care Unit (ICU) with worsening Small Bowel Obstruction (SBO) who is on vasopressors (e.g. norepinephrine) for hypotension?
What is the recommended dose of cephalexin (Cephalexin) for the treatment of mastitis?
What is the recommended timeframe to titrate Amisulpiride (antipsychotic medication) from 400mg to 800mg per day?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question